Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01478048 · ClinicalTrials.gov registry record · Phase 2
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 185
- Enrollment target
NCT01478048 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 185 participants.
The verdict
NCT01478048, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 185 participants
- Enrollment target
Study Summary
The purpose of the study is to determine whether the addition of Elotuzumab to Bortezomib/ Dexamethasone will prolong the time before myeloma worsens \[progression free survival (PFS)\].
Interventions
- DRUG Dexamethasone
- DRUG Bortezomib
- BIOLOGICAL Elotuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2011-11-30 |
| Est. Completion | 2017-04-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01478048
The ClinicalTrials.gov registry entry for NCT01478048 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 185 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT01478048 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01478048 about?
NCT01478048 is a clinical study titled "Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma". The purpose of the study is to determine whether the addition of Elotuzumab to Bortezomib/ Dexamethasone will prolong the time before myeloma worsens \[progression free survival (PFS)\].
What is the current status of trial NCT01478048?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 185 participants. The study started on 2011-11-30. Estimated completion is 2017-04-21.
What interventions are being tested in trial NCT01478048?
The interventions under investigation include: Dexamethasone (DRUG), Bortezomib (DRUG), Elotuzumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01478048?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.